Merck stock analysis
Merck passes 2 of 7 fundamental tests, a score of 3/10. On the daily chart it is in an uptrend, RSI 52, 7% below its 52-week high: uptrend pullback to the 20-day average. Its own volatility puts the likely range at $134.22–$158.71 a month from now and $109.18–$195.10 in a year (68% bands). The last two days of news lean bullish (1 positive, 0 negative stories).
Fundamentals 3/10
- Market cap
- $360.1 B
- P/E · forward
- 115.8 · 15.7
- PEG · P/B
- 2.7 · 8.6
- ROE · net margin
- +7% · +5%
- Revenue · earnings growth
- +5% · —
- Debt / equity
- 128%
- Dividend · beta
- 2.3% · 0.2
- Next results
- 29 Oct 2026
- ✕ ROE above 15%
- ✕ Net margin above 10%
- ✕ Revenue growing over 10%
- ✕ Debt/equity under 100%
- ✓ Positive free cash flow
- ✓ Forward P/E under trailing (earnings expected up)
- ✕ PEG under 2
Swing technicals (daily)
- Trend
- up · 50d above 200d
- RSI(14)
- 52
- 20 / 50 / 200-day avg
- $145.74 / $145.12 / $124.87
- 20-day breakout
- above $153.57 · below $138.80
- ATR(14)
- $3.87 (2.7% a day)
- 52-week range
- $82.01 – $156.92
- Return 3m · 6m · 1y
- +17% · +23% · +72%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | $134.22 – $158.71 (-8% / +9%) |
| 3 mo | $126.23 – $168.74 (-14% / +16%) |
| 6 mo | $118.87 – $179.20 (-19% / +23%) |
| 1 year | $109.18 – $195.10 (-25% / +34%) |
Analysts (25): buy, mean target $158.44 (+9%)
From its own volatility (29% a year), no drift assumed: what its swings allow, not a forecast.
Merck news · last two days
News lean: Bullish · 1 up · 0 down- 23h agoAbbVie vs. Merck: Which Pharma Stock Offers Better Value?Insider Monkey
- 24h agoMerck Stock: Watch This Price, Prepare To Profit From This TradeInvestor's Business Daily
- 24h agoMerck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?Insider Monkey
- 30h agoGoldman Sachs Adjusts Price Target on Merck & Co to $155 From $160MT Newswires
- 45h agoHow Has Merck's Story Changed?Trefis
- 45h agoWhat Could Merck (MRK) Reveal At ESMO 2026 About Its Oncology Pipeline?Simply Wall St.
- 48h agoAMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow24/7 Wall St.
- 2d agoMerck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA VaccineInsider Monkey
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.